Clinical Trial Update: Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer [Phase 4]

View source ↗

Summary

Clinical trial update for a Phase 4 study comparing nimotuzumab plus S-1 versus placebo plus S-1 as maintenance therapy in unresectable pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Unresectable Pancreatic Cancer | Phase 4 | Status: UNKNOWN